Click here to close now.

SYS-CON MEDIA Authors: Mike Kavis, Plutora Blog, Bart Copeland, Andreas Grabner, Liz McMillan

News Feed Item

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU

NEW YORK, Feb. 12, 2014 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisitionIn the recent years several new therapies have been approved in the area of diabetes (SGLT-2, GLP-1 agonists), Multiple Sclerosis, HCV, melanoma and breast cancer from major pharmaceutical companies. Many of them are expected to reach multibillion dollars peak sales in the near-term which is likely to compensate the patent expiry loss in top-line revenue. Novel mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma companies. Most companies are in race to acquire assets in these hot therapy areas. Companies who already have these assets are investing heavily in clinical development programs. The interest in pursuing opportunities in Oncology therapy is unhindered for all major Pharma companies.

Research investments in oncology likely to continue for several more years due to the significant unmet need exist in this area.But for a few companies, patent expiry impact continues to haunt the top-line and they are finding it difficult to replace declining sales with Proprietary pipeline products. Beyond 2013, the impact of patent loss will further aggravate the revenue decline. They have chosen strategies of prioritization pipeline assets, cost efficiency measures, divestment of non-core assets which yield poor margins and increase focus on therapy areas where they have already proven its mettle. Increase in dividend payout and share repurchase are some near term measures where they are actively participating. Gain in financial strength through divestment of non-core assets (OTC, Animal Health, Consumer health, Diagnostics) will be utilized in pursuing opportunities in high margin therapy areas. At the same time it has becoming more difficult to find such lucrative assets because they are scarce and if available are trading at very high premium in speculation of getting acquired (ex. Roche-Alexion).

Going forward, Economies of Scale will also play a major role in swapping the non-core business among major pharma including Vaccines, OTC and animal health to improve margins.Global Pharma continues to remain attractive due to management efforts on the restructuring of entire business model, cost efficiency measures, de-consolidation, acquisition of high value targeted assets, share repurchase program and dividend policy.Global Biopharmaceutical Outlook 2014-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry

Table of contents

Macro Analysis: Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy cash position- Will accelerate Next wave of Targeted Acquisitions

• New Drug Filing Declining but compensated by faster approval with Break through Designation
• FDA Break through designation allowed faster market reach
• R&D strategy re-defined- More focus on early development to improve late stage success
• Recent Restructuring efforts of Major Pharma companies
• Cost efficiency measures and divestments
• Financial Environment favourable for the Next Wave of acquisition

Table 1: Pharma Pipeline allocation changes: 2010-2013
Table 2: Global Pharma –Head count reduction & Share repurchase program
Table 3. Cash, Debt and Mkt Cap Of Global Pharma/ Biotech Companies
Table 4: Cash, Debt and EV of Rising star companies
Chart 1: Cash and Debt of Global Pharma/ Biotech Companies

Company Analysis:
1. AstraZeneca: Early Stage Pipeline Strong; Bold Initiatives Offer Some Relief But Are Not Enough To Hold Pressure
• Long term clinical studies and R&D outlook
• Strengthening business in diabetes: Acquisition from BMY
• Outlook of respiratory franchise going forward: Symbicort and PT003
• Brilinta/Brilique –Prescription Trend and formulary adoption improving but not re?ected in revenues
• The impact of competition on Faslodex
• Late stage development program update:
i) Selumitinib
ii) Lesinurad
iii) Olaparib
iv) Benralizumab
v) Brodalumab
vi) Moxetumomab
vii) Trolokinumab
viii) MEDI4736 (anti-PDL1)
ix) AMP-514
• Key Milestone Table

Table 1: PhIIb combo data of lesinurad in gout pts – allopurinol-inadequate responders
Table 2: Recent acquisition /partnership deals done in 2013
Table 3: Generic exposure thru 2018
Chart 1: Chinese market growth: Global Pharma in 2013

2. Bristol-Myers Squibb: Specialty Biopharma with Oncology Focus Can Give Returns: Nivolumab and Eliquis Success Important

• Snapshots Review on Late stage pipeline assets
• Divestment of diabetes business to AZN – Deal review
• Eliquis Ramp up would be central to BMY's stock price performance in 2014
• Yervoy's potential could be limited by emerging competition
• Ipilimumab status in other indications
• Anti-PD1 antibody (Nivolumab, BMS-936558, PhIII) Immunotherapy (NSCLC, Melanoma)
• Other key Pipeline assets: Elotuzumab
• Impact of generization in topline revenue
• Key Milestones

Table: 1: Anti PD-1 pipeline molecules
Table 2: Ongoing PhIII clinical studies on Anti-PD1
Table 3: Peak sale potential of future blockbusters
Table: 4: Generic exposure thru 2018

3. Eli Lilly: Patent Pressures Aggravated With Undifferentiated Pipeline Assets but
Supporting Diabetes Market Offers a sigh of Relief
• Necitumumab offers sigh of relief but commercial signi?cance limited
• Late Stage Assets Review: PEG-Lispro, LY2963016, Dulaglutide, Empagliflozin, SGLT2 + DPP4 FDC, Solanezumab, Baricitinib, Ixekizumab, Cixutumumab, Ramucirumab
• Litigation of marketed products update: Evista and Alimta
• Key milestones
Table: 1: Competitive landscape – GLP-1 agonist
Table 2: SGLT2 inhibitors- competitive landscape
Table 3: Ongoing PhIII clinical studies of Ramucirumab
Table 4: Patent expiry impact through 2018

4. GlaxoSmithKline: Base Business Provides Sustainability; Several Block Buster's Will Offer Growth!
• Multiple blockbusters emerging in Melanoma, Respiratory and HIV
• MAGE-A3 vaccine in NSCLC
• Anoro (Umeclidinium/Vilanterol, LABA/LAMA FDC-Ellipta device) positioning becomes stronger than LABA+ICS or LABA or LAMA mono in COPD
• Relvar/Breo Ellipta (Vilanterol/Fluticasone FDC): Efficacy and safety data in Asthma and COPD
• Eperzan (Albiglutide): Superior ef?cacy, better tolerability, ease of administration and compliance bene?ts should position Albiglutide better than competition in earlier lines of treatment
• Key Milestones

Table 1: Clinical data of BRAF Inhibitor in Metastatic Melanoma
Table 2: Bydureon, Albiglutide & Victoza- DURATION 6 vs. HARMONY 6, 7

5. Merck: Restructuring Impact And Targeted Focus On Oncology And HCV Will Drive Growth!!
• Detailed data on Odanacatib – Upside lies in the safety pro?les of this drug
• Completion of Mega-trials should ensure R&D cost savings to the tune of $1billion
• R&D Pipeline Update: HCV combo, Lambrolizumab and Corporate Restructuring Program
• Growing evidence base on CV safety of DPP-IV inhibitors
• TECOS should help DPP-IV expand their share in a fast growing but highly genericized diabetes market
• Once weekly DPP-IV - MK-3102 should help Merck carve a share in the ?rst line setting in type 2 diabetes
• HCV Therapy: MK-5172 and MK-8742 combo, Once daily
• Lambrolizumab (MK-3475, anti-PD1) in Second-line NSCLC; Potential additional Indications for anti-PD1
• Merck restructuring Impact going forward is positive for Investor
• Januvia franchise - Reason for de-growth in the US and outlook for the DPP-IV market –Emerging competition from SGLP-2 inhibitors
• Impact of Gardasil and V503: JP Govt. scheduled to review the withheld decision of Gardasil in early 2014
• View on Remicade Biosimilar approval in Europe
• Key Milestone

Table 1: Ongoing clinical trials of Lambrolizumab
Table 2: Competitive landscape of anti-PD1
Chart 1: Late stage pipeline in HCV therapy

6. Pfizer: Dependent on Palbociclib and Prevnar-13 in Adults to Sustain Business!
• Restructuring: Three Major Business Segments
• Xeljanz (tofacitinib)-RA broader label but slower uptake: Limited Opportunity for Xeljanz and forecast $1.2b in peak sales with competition Following
• Prevnar 13 US growth will be driven by approval in adults and outcome of the CAPiTA study data is the key
• Eliquis Superiority claim in Stroke will give an edge over competitor (Peak sales $2.5b)
• Palbociclib (CDK4/6 cell cycle inhibitor, PhIII, ER positive and HER2 negative Breast cancer) - Blockbuster potential -PFE leading the race: Competitors are 1.5 y behind in development
• Dacomitinib (PhIII, secondline NSCLC) –Low potential
• Bococizumab (RN316 (PF-04950615), PCSK9 inhibitor, PhIII, Hypercholesterolemia) –Third entrant will lose its relevance if others succeed
• Advantages and Risks vs. Competitor in anti-PCSK9 area
• Key Milestones

Table 1: Xeljanz: Efficacy comparison with baricitinib
Table 2: Select oral RA drugs in development
Table 3: Ongoing clinical trials: CDK inh.-Palbociclib

7. Novartis: Pipeline Strengthening : De-consolidation Will Provide Targeted Focus
• Respiratory sales ramp to drive sales; Patent expiry pressure immense
• Oncology targeted and cellular therapy approach
• Divestment of blood transfusion unit to Grifols
• String of Pearls- LDK378, Serelaxin followed by breakthrough designation for BYM338 (bimagrumab)
• Gilenya ramp up in Multiple Sclerosis much faster than expected but market ramp up Tec?dera (BiogenIdec) is extraordinary
• SERELAXIN (RLX-030) in Acute Heart Failure – Unmet need would allow an approval-FDA breakthrough designation granted - LCZ696 in chronic heart failure
• Secukinumab in Plaque Psoriasis - Trying To Be Different in a Crowded Space
• Competitive Scenario in Plaque Psoriasis
• PASPORT-Cushings Head to Head Study positive: Sandostatin LAR Replacement ready in active acromegaly
• Signifor/ Pasireotide will penetrate in patients inadequately controlled on Sandostatin. Signifor LAR will take up market share from Sandostatin LAR before the patent expiry in 2017
• Panobinostat in RRMM
• Sandoz growth to be driven by biosimilars and respiratory generics
• Key Milestone Table

Table 1: Competition in Acromegaly
Table 2: PASPORT-Efficacy and safety comparison: Signifor LAR vs. Sandostatin LAR
Table 3: Select late- & mid-stage pipeline: Plaque Psoriasis
Table 4: PhIII Clinical data on Plaque Psoriasis of marketed products

8. Novo Nordisk: GLP-1 and Insulin Market Becoming Too Competitive; Relief Should
Come From Victoza in Obesity
• Novothirteen targets rare, autosomal, niche market
• Competitive pressures on Victoza
• Dulaglutide Phase III data suggests slightly better ef?cacy with once weekly advantage over Victoza
• Levemir under threat from SAN's U300
• Bio-similar insulins impact cannot be neglected
• Liraglutide 3mg obesity regulatory overhang persists
• Regulatory concerns of pancreatitis, thyroid cancer & CV risk for high dose regimen in obesity
• Haemostasis Franchise
• Key Milestone Table

9. Roche: Pricing Power With Strong Foot Hold In Oncology Will Drive Growth
• Strong late stage pipeline will offer potential sustainability and growth
• Superiority of Gazyva against Rituxan in CLL
• Ramp up of Kadcyla in second-line advanced breast cancer patients
• Perjeta -First approved therapy in preoperative, early stage, and ?rst-line HER2 positive breast cancer strengthening its breast cancer franchise
• Further Indication expansion for Perjeta
• RoActemra monotherapy Superior to Humira: ADACTA Study
• Kadcyla: MARIANNE, EMILIA AND APHINITY trials will lend sustainable growth to breast cancer franchise
• Roche to retain all of its current Herceptin sales beyond Patent Expiry in US and EU; Rituxan Biosimilar threat is negligible
• Etrolizumab ( Ulcerative colitis and Crohn's Disease)
• Avastin outlook - 2014 onwards
• Bitopertin (Schizophrenia-negative symptoms)
• Onartuzumab (MetMab, MET positive NSCLC (2nd and 3rd line) and triple negative
• breast cancer)
• Zelboraf ramp up to get impacted by competition from GSK
• MPDL3280A (anti-PDL1 mAB, PhIII, NSCLC, Melanoma)
• Key Milestone Table

Table 1: Major pipeline molecules with expected filing
Table 2: Efficacy and safety comparison of Kadcyla vs. trastuzumab+docetaxel in ?rstline BC (PhII)
Table 3: Ongoing important clinical studies of Kadcyla in late stage HER 2 positive cancer
Table 4: Ongoing clinical trials on biosimilar rituxan
Table 5: Efficacy target profile of Gazyva in clinical studies
Table 6: Clinical data of BRAF inhibitor in metastatic melanoma

10. Sanofi: Sustainable Business but Innovative Pipeline Not Impressive
• R&D Pipeline: Upside limited due to Strong Competition; but orphan indication approval to improve the top-line growth
• Anti-PCSK9 antibody and Dengue Vaccine are potential mega blockbuster candidates, and could make all the difference for SAN's investor but it will take long to deliver
• Lemtrada ramp up in Europe (CR received in the US)
• Lyxumia (Lixisenatide) –US ?ling withdrawn due to want of CV outcome data from FDA and ELIXA outcome and head to head Victoza data
• New Lantus formulation (Insulin U300)
• Lantus/Lixisenatide combination update
• Patent Expiry Impact to continue in 2014
• Aubagio: Except for oral administration and lower discontinuations, there is no differentiation for Aubagio vs. existing treatment options
• Sarilumab ( anti-IL-6R mAB, Rheumatoid arthritis)
• Dengue Vaccine (PhIII)
• Alirocumab anti-PCSK6, Hypercholesterolemia) –CV outcome study will push the ?ling in 2018
• Key Milestone

Table 1: Sarilumab ACR results at week 24
Table 2: Alicromumab PhIII ODYSSY Program

Annexure I: Clinical and Regulatory Milestones In 2014
Annexure II: Global Pharma- PhII and PhIII Pipeline Candidates
Annexure III: Pipeline Peak Sale Potential Thru 2018
Annexure IV: Impact of Patent Expiry Thro 2018
Annexure V: Drugs Losing Patent Protection By 2018

Companies Mentioned

AstraZeneca,Bristol-Myers Squibb, Eli Lilly, Merck,Novo Nordisk, Novartis, Pfizer, Roche,GlaxoSmithKline

To order this report: Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The explosion of connected devices / sensors is creating an ever-expanding set of new and valuable data. In parallel the emerging capability of Big Data technologies to store, access, analyze, and react to this data is producing changes in business models under the umbrella of the Internet of Things (IoT). In particular within the Insurance industry, IoT appears positioned to enable deep changes by altering relationships between insurers, distributors, and the insured. In his session at @Things...
PubNub on Monday has announced that it is partnering with IBM to bring its sophisticated real-time data streaming and messaging capabilities to Bluemix, IBM’s cloud development platform. “Today’s app and connected devices require an always-on connection, but building a secure, scalable solution from the ground up is time consuming, resource intensive, and error-prone,” said Todd Greene, CEO of PubNub. “PubNub enables web, mobile and IoT developers building apps on IBM Bluemix to quickly add sc...
The cloud has transformed how we think about software quality. Instead of preventing failures, we must focus on automatic recovery from failure. In other words, resilience trumps traditional quality measures. Continuous delivery models further squeeze traditional notions of quality. Remember the venerable project management Iron Triangle? Among time, scope, and cost, you can only fix two or quality will suffer. Only in today's DevOps world, continuous testing, integration, and deployment upend...
Data-intensive companies that strive to gain insights from data using Big Data analytics tools can gain tremendous competitive advantage by deploying data-centric storage. Organizations generate large volumes of data, the vast majority of which is unstructured. As the volume and velocity of this unstructured data increases, the costs, risks and usability challenges associated with managing the unstructured data (regardless of file type, size or device) increases simultaneously, including end-to-...
Sensor-enabled things are becoming more commonplace, precursors to a larger and more complex framework that most consider the ultimate promise of the IoT: things connecting, interacting, sharing, storing, and over time perhaps learning and predicting based on habits, behaviors, location, preferences, purchases and more. In his session at @ThingsExpo, Tom Wesselman, Director of Communications Ecosystem Architecture at Plantronics, will examine the still nascent IoT as it is coalescing, includin...
The excitement around the possibilities enabled by Big Data is being tempered by the daunting task of feeding the analytics engines with high quality data on a continuous basis. As the once distinct fields of data integration and data management increasingly converge, cloud-based data solutions providers have emerged that can buffer your organization from the complexities of this continuous data cleansing and management so that you’re free to focus on the end goal: actionable insight.
Between the compelling mockups and specs produced by your analysts and designers, and the resulting application built by your developers, there is a gulf where projects fail, costs spiral out of control, and applications fall short of requirements. In his session at DevOps Summit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, will present a new approach where business and development users collaborate – each using tools appropriate to their goals and expertise – to build mo...
Operational Hadoop and the Lambda Architecture for Streaming Data Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing...
The Internet of Things (IoT) is causing data centers to become radically decentralized and atomized within a new paradigm known as “fog computing.” To support IoT applications, such as connected cars and smart grids, data centers' core functions will be decentralized out to the network's edges and endpoints (aka “fogs”). As this trend takes hold, Big Data analytics platforms will focus on high-volume log analysis (aka “logs”) and rely heavily on cognitive-computing algorithms (aka “cogs”) to mak...
When it comes to the Internet of Things, hooking up will get you only so far. If you want customers to commit, you need to go beyond simply connecting products. You need to use the devices themselves to transform how you engage with every customer and how you manage the entire product lifecycle. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, will show how “product relationship management” can help you leverage your connected devices and the data th...
In the consumer IoT, everything is new, and the IT world of bits and bytes holds sway. But industrial and commercial realms encompass operational technology (OT) that has been around for 25 or 50 years. This grittier, pre-IP, more hands-on world has much to gain from Industrial IoT (IIoT) applications and principles. But adding sensors and wireless connectivity won’t work in environments that demand unwavering reliability and performance. In his session at @ThingsExpo, Ron Sege, CEO of Echelon...
With several hundred implementations of IoT-enabled solutions in the past 12 months alone, this session will focus on experience over the art of the possible. Many can only imagine the most advanced telematics platform ever deployed, supporting millions of customers, producing tens of thousands events or GBs per trip, and hundreds of TBs per month. With the ability to support a billion sensor events per second, over 30PB of warm data for analytics, and hundreds of PBs for an data analytics arc...
One of the biggest impacts of the Internet of Things is and will continue to be on data; specifically data volume, management and usage. Companies are scrambling to adapt to this new and unpredictable data reality with legacy infrastructure that cannot handle the speed and volume of data. In his session at @ThingsExpo, Don DeLoach, CEO and president of Infobright, will discuss how companies need to rethink their data infrastructure to participate in the IoT, including: Data storage: Understand...
Since 2008 and for the first time in history, more than half of humans live in urban areas, urging cities to become “smart.” Today, cities can leverage the wide availability of smartphones combined with new technologies such as Beacons or NFC to connect their urban furniture and environment to create citizen-first services that improve transportation, way-finding and information delivery. In her session at @ThingsExpo, Laetitia Gazel-Anthoine, CEO of Connecthings, will focus on successful use c...
Sensor-enabled things are becoming more commonplace, precursors to a larger and more complex framework that most consider the ultimate promise of the IoT: things connecting, interacting, sharing, storing, and over time perhaps learning and predicting based on habits, behaviors, location, preferences, purchases and more. In his session at @ThingsExpo, Tom Wesselman, Director of Communications Ecosystem Architecture at Plantronics, will examine the still nascent IoT as it is coalescing, includin...